Lynk reports 76-week durability for JAK1 inhibitor in hard-to-treat rheumatoid arthritis

Overview

Updated 2 hours ago

Roughly a third of rheumatoid arthritis patients don't get adequate relief from biologic drugs, the standard treatment after methotrexate. Lynk Pharmaceuticals reported that its oral JAK1 inhibitor zemprocitinib kept 91.8% of those patients at an ACR20 response through 76 weeks.

The results come from a 430-patient Phase III trial in biologic-inadequate responders, a group that's hard to treat. The durability matters because the JAK inhibitor class carries FDA safety warnings about cardiovascular and cancer risk, so a new entrant must show sustained benefit without piling on harm.

Why it matters

If approved, zemprocitinib offers RA patients who failed biologics a daily pill with sustained response, and tests whether safer JAK inhibitors are possible.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

91.8%

ACR20 response at Week 76

Patients on continuous zemprocitinib who maintained the primary efficacy measure through 76 weeks.

80.5%

ACR50 response at Week 76

Half or better improvement in tender and swollen joint counts and other measures.

62.4%

ACR70 response at Week 76

Deep response level, up from 52.5% at Week 52 as treatment continued.

430

Patients randomized

Adults with moderate-to-severe active RA with inadequate response or intolerance to biologic DMARDs.

Voices

Curated perspectives — historical figures and your fellow readers.

People Involved

Xiaofeng Zeng

Principal investigator, Phase III zemprocitinib RA trial

Professor at Peking Union Medical College Hospital and the Chinese Academy of Medical Sciences

Organizations Involved

Lynk Pharmaceuticals

Clinical-stage biotech

Developer of zemprocitinib (LNK01001)

Clinical-stage biotech focused on immune and inflammatory diseases, with operations in Hangzhou, Shanghai and Boston.

Simcere Pharmaceutical Group

Chinese pharmaceutical company

Commercialization partner for zemprocitinib in Greater China

Simcere partnered with Lynk in March 2022 to jointly commercialize zemprocitinib for rheumatoid arthritis and ankylosing spondylitis across Greater China.

Timeline

March 2022 October 2026

4 events Latest: Today

Tap a bar to jump to that date

October 2026
Long-term Week 52 and 76 results reported
Today Clinical Results

Sustained ACR responses, low disease activity and physical function through 76 weeks; no new safety signals.
Today
January 2026
Positive Phase III topline announced
Clinical Results

ACR20 at Week 24 hit 79.1% versus 39.7% for placebo (p<0.0001); primary and key secondary endpoints met.
January 12th, 2026
2026
24-week results presented at EULAR 2026
Conference

Double-blind period efficacy and safety data presented at the EULAR 2026 Congress (Abstract OP0208).
2026
March 2022
Lynk and Simcere sign commercialization pact
Partnership

Simcere gained commercialization rights for zemprocitinib in RA and ankylosing spondylitis across Greater China.
March 2022

Scenarios

China's NMPA approves zemprocitinib for rheumatoid arthritis

Likely Resolves by End of 2027

Discussed by: Lynk's stated regulatory trajectory — its atopic dermatitis NDA has already been accepted for review by the NMPA

Lynk files a New Drug Application for RA in China on the strength of the Week 24 and long-term data. Given that the AD application was accepted, a same-agency RA filing is the obvious next step, with approval likely contingent on the safety profile holding up in the submitted dataset.

Lynk reports topline results from ankylosing spondylitis Phase III

Possible Resolves by Q2 2027

Discussed by: Company disclosures confirming an ongoing Phase III program in ankylosing spondylitis

The ankylosing spondylitis trial completes and Lynk announces topline efficacy and safety. A positive readout would extend zemprocitinib's addressable patient base beyond RA and atopic dermatitis, giving Simcere a second indication to commercialize.

Lynk signs a global licensing deal for zemprocitinib

Possible Resolves by Q2 2028

Discussed by: Lynk's Boston operations and the precedent of its Simcere partnership in Greater China

After the durable RA data and the accepted atopic dermatitis filing, Lynk seeks a partner to develop and commercialize zemprocitinib outside Greater China, where it has no commercial footprint. A deal would bring in capital and regulatory expertise for markets like the US and Europe.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

Published November 2020

Baricitinib 3-year long-term extension data (2020)

Baricitinib, a first-generation JAK inhibitor, was studied in long-term extensions of the RA-BEGIN and RA-BEAM trials. Up to 59% of methotrexate-inadequate responders reached low disease activity (SDAI ≤11) at week 148, and up to 34% of DMARD-naive patients reached remission.

Then

Demonstrated that JAK inhibitors could sustain efficacy over roughly three years with acceptable tolerability.

Now

Set the durability benchmark for oral RA therapies and supported baricitinib's continued use despite later class-wide safety warnings.

Why this matters now

Zemprocitinib's 76-week ACR and low-disease-activity data are measured against this established JAK-class durability standard.

2021

JAK inhibitor class safety scrutiny (2021)

The FDA added boxed warnings to tofacitinib, baricitinib and upadacitinib citing elevated cardiovascular and cancer risk, following results from the ORAL Surveillance study of tofacitinib in RA patients over 50 with cardiovascular risk factors.

Then

Prescribing for first-generation JAK inhibitors tightened, with warnings steering use toward patients who failed other treatments.

Now

Created a higher bar for any new JAK inhibitor to prove long-term safety, not just efficacy, before broad adoption.

Why this matters now

Lynk highlights 'cleaner lab parameters' and no new safety signals through 76 weeks as evidence that a second-generation selective JAK1 inhibitor can differentiate on safety.